GILD News 71.60 04/21/2014 21:17:36 Gilead Sciences (GILD)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gilead Sciences (GILD) 71.60 $GILD

Gilead Sovaldi Drug Sales Key In Q1 Earnings Report
at Investor's Business Daily - Mon Apr 21, 5:34PM CDT
In a week filled with earnings reports from big-cap biotechs, Gilead Sciences' (GILD) might be the most watched as it reveals its first full quarter of sales for blockbuster hepatitis C drug Sovaldi. Gilead reports after the market close Tuesday....

What to Watch for in Biotech Earnings This Week
George Budwell, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Biotech stocks started the year off on a tear but have moved lower lately in dramatic fashion. For instance, the iShares Nasdaq Biotech Index is now down over 2% for the year, after gaining double digits at one point in early February. Pundits and...

Most active Nasdaq-traded stocks
AP - Mon Apr 21, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:

Stocks Rise; Valeant, Netflix Soar After Hours
at Investor's Business Daily - Mon Apr 21, 4:00PM CDT
Stocks rose Monday, with the S&P 500 notching its fifth straight gain, as quarterly earnings reports continue to roll out. Valeant Pharmaceuticals (VRX) soared in post-session trading after The Wall Street Journal reported that the Canadian drugmaker...

SmarTrend Watching for Potential Pullback in Shares of Gilead Sciences After 2.29% Gain
Comtex SmarTrend(R) - Mon Apr 21, 3:41PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $69.40 to a high of $71.99. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $70.64 on volume of 17.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 2.29%
Comtex SmarTrend(R) - Mon Apr 21, 3:41PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $69.40 to a high of $71.99. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $70.64 on volume of 17.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Gilead Sciences' New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA
Business Wire - Mon Apr 21, 3:30PM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's refiling of two New Drug Applications (NDA) for cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of the protease inhibitors atazanavir and darunavir to enable once-daily dosing of these medicines in HIV therapy, and elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced adults. The FDA has set target review dates under the Prescription Drug User Fee Act (PDUFA) of October 3, 2014 for cobicistat and October 4, 2014 for elvitegravir.

Gilead Q1 Its First Full Quarter With Sovaldi
at Investor's Business Daily - Mon Apr 21, 12:44PM CDT
In a week filled with earnings reports from big-cap biotechs, Gilead Sciences' (GILD) might be the most watched as it reveals its first full quarter of sales for blockbuster hepatitis C drug Sovaldi. Gilead reports after the market close Tuesday....

Gilead Sciences (GILD) Breaks Through Resistance at $70.73
Comtex SmarTrend(R) - Mon Apr 21, 12:29PM CDT
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $69.91 and have already reached the first level of resistance at $70.73. Analysts will be watching for a cross of the next upside pivot targets of $71.46 and $73.01.

Midday Glance: Biotechnology companies
AP - Mon Apr 21, 12:20PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:

Will This Report Help Gilead Sciences (GILD) Stock Today?
at The Street - Mon Apr 21, 11:31AM CDT
Gilead Sciences (GILD) has an estimated total return of 45.4% according to a research note published by Citigroup.

Jim Cramer: We're Still in the Tech Woods
at The Street - Mon Apr 21, 10:25AM CDT
When people attach such frothy numbers to IPOs, we have problems.

Will Gilead (GILD) Beat Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 9:50AM CDT
Gilead is set to report first quarter 2014 results on Apr 22 after the market closes

Early Glance: Biotechnology companies
AP - Mon Apr 21, 9:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:

3 Reasons the Market Is Down on Gilead Sciences
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
After a solid two-year run, Gilead Sciences   has fallen from investors graces, down for the year. The biotech has become increasingly reliant on its hepatitis C drug Sovaldi, with competition from  AbbVie and  Merck  around the corner. In the...

Jim Cramer: We're in the Grips of a Struggle
at The Street - Fri Apr 18, 12:51PM CDT
Companies that are inventing incredibly important drugs go down almost every day.

Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings
at Investor's Business Daily - Fri Apr 18, 11:12AM CDT
Can biotech stocks bounce back? As recently as last month, the Medical-Biomed/Biotech group was ranked No. 1 out of IBD's 197 industries. But it's been dead last over the last four weeks, plunging 22.1%. That partly reflects growth stocks overall...

Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 5:30PM CDT
Investors focusing on Johnson and Johnson 's 3.5% top-line revenue growth in the first quarter are likely walking away unimpressed. However, tepid results in the company's medical device and consumer goods business mask much stronger growth in...

Final Glance: Biotechnology companies
AP - Thu Apr 17, 5:01PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:

Has A Streamlined FDA Raised The Value Of Drug Stocks?
at Investor's Business Daily - Thu Apr 17, 4:33PM CDT
Last month, three Democrats from the U.S. Congress sent a now-famous letter to Gilead Sciences (GILD) questioning the $84,000 price of its new blockbuster hepatitis C medicine, Sovaldi. Among the reasons raising suspicions that the price didn't need...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 438

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 325

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 365

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 280

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 210

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 278

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 261

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 443

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 448

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 349

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

ANSI Electric Vehicles Standards Panel Releases New Report

Updated Category News Views 285

ANSI Electric Vehicles Standards Panel Releases New Report In a significant step towards enhancing the adoption of electric vehicles (EVs) and their infrastructure, the American National Standards Institute (ANSI) has unveiled the May 2025 Gaps Progress Report. This report is integral to understanding the collaborative efforts being made by various stakeholders to bridge...

Continue Reading
Oklahoma Startups Thrive in Catalyst Accelerator Boot Camp

Updated Category News Views 575

Catalyst Accelerator Empowers Startups through Innovative Boot Camp The Catalyst Accelerator is thrilled to unveil a significant opportunity for six emerging tech startups in Oklahoma. This new initiative, the Government Business Boot Camp, is fashioned to equip these talented companies with the insights and tools necessary to succeed in government contracting. In...

Continue Reading
Legal Action Commences for Biogen Inc. (NASDAQ: BIIB) Investors

Updated Category News Views 200

Legal Investigation for Biogen Inc. Stockholders Bragar Eagel & Squire, P.C., a reputable law firm, is currently investigating claims against Biogen Inc. (NASDAQ: BIIB) on behalf of long-term stockholders. This investigation follows the recent filing of a class action complaint aimed at holding the company accountable for alleged misleading statements regarding its...

Continue Reading
Understanding the Urgent Need for Data Governance in AI

Updated Category News Views 133

The Growing Importance of Data Governance in AI As the landscape of business evolves, the adoption of artificial intelligence (AI) in enterprises has surged, leading to significant transformations in operations, development, and knowledge work. However, this rapid integration of AI solutions has brought about new data risks that traditional technologies often overlook....

Continue Reading
Oracle's High Debt Levels Raise Concerns for Investors

Updated Category News Views 797

Oracle’s Debt Concerns Illuminate Financial Landscape In a recent analysis, a leading strategist from J.P. Morgan has drawn attention to the substantial debt levels of Oracle Corp. (NYSE: ORCL). Reporting a staggering 500% debt-to-equity ratio, Oracle’s financial commitments appear considerably higher when compared to other companies in the sector. Analysis from J.P....

Continue Reading